|Bid||342.66 x 100|
|Ask||346.13 x 600|
|Day's Range||337.50 - 345.00|
|52 Week Range||244.28 - 348.84|
|PE Ratio (TTM)||21.16|
|Earnings Date||Jan 25, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||361.15|
A Cambridge startup led by former executives at Pfizer and Biogen has attracted $58 million in financing as it seeks to pioneer a new class of drugs that can tweak the immune system without triggering major side effects. Pandion Therapeutics announced the Series A round on Thursday along with the appointments of Anthony Coyle as CEO and Jo Viney as chief scientific officer. Coyle previously led Pfizer’s (PFE) Centers for Therapeutic Innovation, a research and development group with offices in Cambridge, New York and California, while Viney led Biogen’s (BIIB) immunology research unit.
Big drugmakers are head over heels over the recent tax reform bill, in part because it allows them to pay a discounted tax rate on repatriated cash — that is, profits held overseas that are brought back to the U.S. Support for the legislation has emerged as a major theme of this week’s J.P. Morgan conference in San Francisco. Biogen (BIIB), the state’s largest independent drugmaker, joined the chorus of praise during a presentation on Monday. During the presentation, CFO Jeff Capello said that Biogen’s 2018 rate “should drop by a couple hundred basis points,” or a couple percent.
As we discussed earlier, Ionis Pharmaceuticals (IONS) is one of the leading biopharmaceutical companies focused on discovering, developing, and commercializing RNA-targeted (ribonucleic acid) therapies. Ionis has created a drug discovery platform and developed many drugs for the treatment of various life-threatening diseases through this broadly applicable platform. Ionis’s revenue sources include its commercial revenue, including its Spinraza royalties and licensing and royalty revenues, and its research and development revenue under its collaborative agreements.
As we discussed earlier, Incyte (INCY) reported a 41.6% rise in its revenue to $381.5 million in 3Q17. Further, Wall Street analysts expect a 26.7% rise in Incyte’s revenue to $413.8 million in 4Q17 and a 35.9% rise in its revenue to $1.5 billion for the entirety of 2017. Incyte’s stock price has fallen nearly 4.3% over the last 12 months and nearly 3.9% year-to-date in 2018.
NEW YORK, NY / ACCESSWIRE / January 9, 2018 / Biogen shares slipped on Monday after it was revealed that a competitor, AveXis, could have a significant delay in a medicine that could compete against Spinraza. ...
Efforts to find treatments for Alzheimer’s disease suffered blows in recent days, but many companies, scientists and investors are still optimistic that they can find a way to treat the memory-robbing ...
Biogen (BIIB) slipped to the bottom of the S&P 500 on Monday, following disappointing drug results from a competitor late Friday. Biogen lost $12.84, or 3.7%, to $321.65, while the S&P 500 gained 4.56 ...
With pharma major, Pfizer (PFE), announcing its intention to drop plans to develop treatments for Alzheimer's and certain other disease areas, here is a look at what is going on in this corner of the market.
Biogen and Ionis are unlikely to see a competitor to Spinraza in 2018, as rival AveXis faces a significant delay for its competing drug.
Biogen and Ionis' Spinraza will likely top fourth-quarter expectations, but at least one analyst says longer-term views are somewhat high.
In an exclusive CNBC interview Michel Vounatsos, Biogen CEO talks to CNBC's Meg Tirrell at the J.P. Morgan Health Care Conference about investing in health care under President Trump and the impact of tax reform on mergers and acquisition. Also Vounats...